• Cryptocurrencies
  • Voorspellingsmarkten
  • Nieuws
  • Agentisch Handelen
  • Artikelen
  • Competities

Zoeken Cryptocurrencies

Trends Cryptocurrencies

CoinRithm

Bedrijf

Rechtspersoon
Bees-x Limited
Bedrijfsnummer
13308136
Opgericht in
England and Wales
Statutaire zetel
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm is een informatie- en onderzoeksdienst van Bees-x Limited. Het is niet door de Financial Conduct Authority (FCA) gemachtigd om gereguleerde activiteiten uit te voeren, en niets op deze site vormt financieel advies.

Ontdekken

CryptocurrenciesVoorspellingsmarktenNieuwsArtikelenAgent ArenaCompetities

Functies

DashboardNephandelAgentisch HandelenPortefeuilleVolglijstInstellingen

Bedrijf

Over OnsMethodologieVoor de klasGebruiks- voorwaardenPrivacybeleidCookiebeleidVrijwaring

Ondersteuning

KlantenserviceFAQOntwikkelaarskitMCP-documentatie

Sociale Media

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Rechten voorbehouden.
Verkrijgbaar via Google PlayDownloaden in de App Store
  • Home
  • MarktenVoorspellingsmarkten
  • Nieuws
  • Dashboard
  1. Voorspellingsmarkten
  2. Regelgeving
  3. FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)
FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)

FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)

RegelgevingOne-OffHealth & Medicine6mnd
KalshiKalshiBeschikbaarheid controlerenKYC vereist2% kosten
Huidige impliciete kans
Ja
Ja 0%
Marktkwaliteit

24 / 100

Lage kwaliteit
24u volume

€ 0

Liquiditeit

€ 0

Lage liquiditeit
Bied / Laat

61.0% / 69.0%

Spread

13.1%

Brede spread
Marktdata

Bijgewerkt 3 minuten geleden

17 jun 26, 21:001 jan 27, 4:59

Trends

Uitkomst24uKans
Ja
Ja
0%
Nee
Nee
100%

Gekozen uitkomst

Yes0%

Regels

If the FDA's decision on DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • DTX401 (pariglasgene brecaparvovec) is a one-time gene therapy developed by Ultragenyx Pharmaceutical to treat Glycogen Storage Disease Type Ia (GSDIa), a rare inherited disorder in which the liver cannot properly release stored sugar into the bloodstream.
  • Think of it like installing a corrected instruction manual inside liver cells: after a single infusion, the therapy is designed to restore the missing enzyme activity — glucose-6-phosphatase — so the liver can once again regulate blood sugar on its own.
  • In the Phase 3 GlucoGene trial , DTX401 produced a statistically significant 41.3% mean reduction in daily cornstarch intake at Week 48 versus 10.3% for placebo (p<0.0001), with durability data at 96 weeks showing approximately 60–61% reductions.

Gerelateerde Markten

Manifold Markets

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

€ 994,7
Ja: 22.2%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Will China have more phase 3 drug trials than the United States in year X?

€ 367,9
2026: 33%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Will estradiol be available over-the-counter in the US before 2030?

€ 303
Ja: 8.2%Manifold MarketsMANIFOLD MARKETS
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

€ 0
Ja: 0%KalshiKALSHI
Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

€ 38,2K
Ja: 4%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

€ 5,2K
Ja: 11%PolymarketPOLYMARKET

Actief in deze onderwerpen

BitcoinBTC$64,565.28-1.93%EthereumETH$1,754.71-2.39%SolanaSOL$72.38-1.70%DogecoinDOGE$0.0862-1.45%XRPXRP$1.19-2.25%BNBBNB$602.70-0.56%

Gerelateerd Nieuws

Binance MiCA License Application Cleared by Greek Regulator, June 30 Update AwaitedBlockchain ReporterCLARITY Act faces ethics showdown as David Nage eyes July voteCrypto NewsBinance EU Access at Risk as Greek Regulator Set to Reject MiCA License BidBlockchain ReporterSolana Institute warns Senate against weakening CLARITY ActCrypto NewsSummer of crypto (regs): State of Crypto CoindeskPhilippine Central Bank Bars VASPs From Listing Privacy CoinsBlockchain Reporter

Regels

If the FDA's decision on DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • DTX401 (pariglasgene brecaparvovec) is a one-time gene therapy developed by Ultragenyx Pharmaceutical to treat Glycogen Storage Disease Type Ia (GSDIa), a rare inherited disorder in which the liver cannot properly release stored sugar into the bloodstream.
  • Think of it like installing a corrected instruction manual inside liver cells: after a single infusion, the therapy is designed to restore the missing enzyme activity — glucose-6-phosphatase — so the liver can once again regulate blood sugar on its own.
  • In the Phase 3 GlucoGene trial , DTX401 produced a statistically significant 41.3% mean reduction in daily cornstarch intake at Week 48 versus 10.3% for placebo (p<0.0001), with durability data at 96 weeks showing approximately 60–61% reductions.